Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor

Molecular Immunology

Volumn 50, Issue 1-2, 2012, Pages 35-41

  Behdani, Mahdi ^a   Zeinali, Sirous ^a   Khanahmad, Hossein ^a   Karimipour, Morteza ^a   Asadzadeh, Nader ^b   Azadmanesh, Keyhan ^a   Khabiri, Alireza ^a   Schoonooghe, Steve ^c,d   Habibi Anbouhi, Mahdi ^a   Hassanzadeh Ghassabeh, Gholamreza ^c,d   Muyldermans, Serge ^c,d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b Department of Animal Breeding and Genetics   (Iran)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Angiogenesis; Nanobody; VEGFR2

Indexed keywords

ANGIOGENIC FACTOR; NANOPARTICLE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODY SPECIFICITY; CAMELIDS, NEW WORLD; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNE SERA; KINETICS; MALE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; SURFACE PLASMON RESONANCE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

CAMELIDAE; CAMELUS DROMEDARIUS;

EID: 84857060448     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.11.013     Document Type: Article

References (47)

1. Ahmadvand D., Rasaee M.J., Rahbarizadeh F., Kontermann R.E., Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol. 2009, 46(8-9):1814-1823.
2. Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997, 414(3):521-526.
3. Backer M.V., Backer J.M. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjug. Chem. 2001, 12(6):1066-1073.
4. Bhargava P., Robinson M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr. Oncol. Rep. 2011, 13(2):103-111.
5. Boldicke T., Weber H., Mueller P.P., Barleon B., Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J. Immunol. Methods 2005, 300(1-2):146-159.
6. Bond C.J., Marsters J.C., Sidhu S.S. Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries. J. Mol. Biol. 2003, 332(3):643-655.
7. Buelens K., Hassanzadeh-Ghassabeh G., Muyldermans S., Gils A., Declerck P.J. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J. Thromb. Haemost. 2010, 8(6):1302-1312.
8. Conrath K.E., Lauwereys M., Galleni M., Matagne A., Frere J.M., Kinne J., Wyns L., Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 2001, 45(10):2807-2812.
9. Dougher-Vermazen M., Hulmes J.D., Bohlen P., Terman B.I. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem. Biophys. Res. Commun. 1994, 205(1):728-738.
10. Doyle P.J., Arbabi-Ghahroudi M., Gaudette N., Furzer G., Savard M.E., Gleddie S., McLean M.D., Mackenzie C.R., Hall J.C. Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Mol. Immunol. 2008, 45(14):3703-3713.
11. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8(8):579-591.
12. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009, 20(4):158-163.
13. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175(3):409-416.
14. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6(4):273-286.
15. Goldman E.R., Anderson G.P., Liu J.L., Delehanty J.B., Sherwood L.J., Osborn L.E., Cummins L.B., Hayhurst A. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal. Chem. 2006, 78(24):8245-8255.
16. Hmila I., Saerens D., Ben Abderrazek R., Vincke C., Abidi N., Benlasfar Z., Govaert J., El Ayeb M., Bouhaouala-Zahar B., Muyldermans S. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 2010, 24(9):3479-3489.
17. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 2007, 19(10):2003-2012.
18. Huang J., Tan Y., Tang Q., Liu X., Guan X., Feng Z., Zhu J. A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes. Cytotechnology 2010, 62(1):61-71.
19. Kendrew J., Eberlein C., Hedberg B., McDaid K., Smith N.R., Weir H.M., Wedge S.R., Blakey D.C., Foltz I., Zhou J., Kang J.S., Barry S.T. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol. Cancer Ther. 2011, 10(5):770-783.
20. Kou B., Li Y., Zhang L., Zhu G., Wang X., Xia J., Shi Y. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol. 2004, 76(2):129-137.
21. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001, 61(1):39-44.
22. Lafaye P., Achour I., England P., Duyckaerts C., Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 2009, 46(4):695-704.
23. Lefranc M.P., Pommie C., Kaas Q., Duprat E., Bosc N., Guiraudou D., Jean C., Ruiz M., Da Piedade I., Rouard M., Foulquier E., Thouvenin V., Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev. Comp. Immunol. 2005, 29(3):185-203.
24. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer 2002, 97(3):393-399.
25. Meissner M., Doll M., Hrgovic I., Reichenbach G., Konig V., Hailemariam-Jahn T., Gille J., Kaufmann R. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J. Invest. Dermatol. 2011, 131(6):1356-1364.
26. Miao H.Q., Hu K., Jimenez X., Navarro E., Zhang H., Lu D., Ludwig D.L., Balderes P., Zhu Z. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem. Biophys. Res. Commun. 2006, 345(1):438-445.
27. Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol. 2001, 74(4):277-302.
28. Muyldermans S., Baral T.N., Retamozzo V.C., De Baetselier P., De Genst E., Kinne J., Leonhardt H., Magez S., Nguyen V.K., Revets H., Rothbauer U., Stijlemans B., Tillib S., Wernery U., Wyns L., Hassanzadeh-Ghassabeh G., Saerens D. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 2009, 128(1-3):178-183.
29. Oliveira S., Schiffelers R.M., van der Veeken J., van der Meel R., Vongpromek R., van Bergen En Henegouwen P.M., Storm G., Roovers R.C. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J. Control. Release 2010, 145(2):165-175.
30. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7(5):359-371.
31. Omidfar K., Rasaee M.J., Modjtahedi H., Forouzandeh M., Taghikhani M., Bakhtiari A., Paknejad M., Kashanian S. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol. 2004, 25(4):179-187.
32. Rahbarizadeh F., Ahmadvand D., Sharifzadeh Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest. 2011, 40(3):299-338.
33. Rahbarizadeh F., Rasaee M.J., Forouzandeh Moghadam M., Allameh A.A., Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid. Hybridomics 2004, 23(3):151-159.
34. Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr. Pharm. Des. 2009, 15(4):345-352.
35. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.J., Revets H., de Haard H.J., van Bergen en Henegouwen P.M. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol. Immunother. 2007, 56(3):303-317.
36. Roskoski R. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2008, 375(3):287-291.
37. Saerens D., Ghassabeh G.H., Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 2008, 8(5):600-608.
38. Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep. 2011, 13(2):97-102.
39. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., Leong S., O'Bryant C., Chow L.Q., Serkova N.J., Meropol N.J., Lewis N.L., Chiorean E.G., Fox F., Youssoufian H., Rowinsky E.K., Eckhardt S.G. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28(5):780-787.
40. Spratlin J.L., Mulder K.E., Mackey J.R. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol. 2010, 6(7):1085-1094.
41. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28(10):2731-2739.
42. Thys B., Schotte L., Muyldermans S., Wernery U., Hassanzadeh-Ghassabeh G., Rombaut B. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Res. 2010, 87(2):257-264.
43. Ton N.C., Parker G.J., Jackson A., Mullamitha S., Buonaccorsi G.A., Roberts C., Watson Y., Davies K., Cheung S., Hope L., Power F., Lawrance J., Valle J., Saunders M., Felix R., Soranson J.A., Rolfe L., Zinkewich-Peotti K., Jayson G.C. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2007, 13(23):7113-7118.
44. Veggiani G., Ossolengo G., Aliprandi M., Cavallaro U., de Marco A. Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1. Biochem. Biophys. Res. Commun. 2011, 408(4):692-696.
45. Watanabe H., Mamelak A.J., Weiss E., Wang B., Freed I., Brice A.K., Wachtman L., Gabrielson K.L., Yokota N., Hicklin D.J., Kerbel R.S., Haas M., Sauder D.N. Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin. Cancer Res. 2005, 11(1):407-409.
46. Youssoufian H., Hicklin D.J., Rowinsky E.K. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin. Cancer Res. 2007, 13(18 Pt 2):5544-5548.
47. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9(1):28-39.